Mutations in the ANGPTL3 Gene and Familial Combined Hypolipidemia: A Clinical and Biochemical Characterization

Biological, clinical and population relevance of 95 loci for blood lipids

Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487 · see citing works

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9

Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381 · see citing works

Exome Sequencing, <i>ANGPTL3</i> Mutations, and Familial Combined Hypolipidemia

Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754 · see citing works

Report of the Conference on Low Blood Cholesterol: Mortality Associations.

Jacobs, D. R., Blackburn, H., HIGGINS, M. W., REED, D. M., Iso, H., McMillan, G. C., Neaton, J. D., Nelson, J., Potter, J., & Rifkind, B. M. (1992) · Circulation · doi:10.1161/01.cir.86.3.1046 · Cited by 718 · see citing works

Transgenic Angiopoietin-Like (Angptl)4 Overexpression and Targeted Disruption of Angptl4 and Angptl3: Regulation of Triglyceride Metabolism

Köster, A., Chao, Y. B., Mosior, M., Ford, A., Gonzalez-DeWhitt, P. A., Hale, J. E., Li, D., Qiu, Y., Fraser, C. C., Yang, D. D., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0476 · Cited by 427 · see citing works

Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans

Romeo, S., Wu, Y., Kozlitina, J., Pennacchio, L. A., Boerwinkle, E., Hobbs, H. H., & Cohen, J. C. (2008) · Journal of Clinical Investigation · doi:10.1172/jci37118 · Cited by 422 · see citing works

ANGPTL3 Decreases Very Low Density Lipoprotein Triglyceride Clearance by Inhibition of Lipoprotein Lipase

Shimizugawa, T., Ono, M., Shimamura, M., Yoshida, K., Ando, Y., Koishi, R., Ueda, K., Inaba, T., Minekura, H., Kohama, T., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203215200 · Cited by 370 · see citing works

Effects of free fatty acids (FFA) on glucose metabolism: Significance for insulin resistance and type 2 diabetes

Boden, G. (2003) · Experimental and Clinical Endocrinology &amp; Diabetes · doi:10.1055/s-2003-39781 · Cited by 348 · see citing works

Angiopoietin-Like Protein3 Regulates Plasma HDL Cholesterol Through Suppression of Endothelial Lipase

Shimamura, M., Matsuda, M., Yasumo, H., Okazaki, M., Fujimoto, K., Kono, K., Shimizugawa, T., Ando, Y., Koishi, R., Kohama, T., et al. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000252827.51626.89 · Cited by 297 · see citing works

Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease

Abifadel, M., Rabès, J., Devillers, M., Münnich, A., Erlich, D., Junien, C., Varret, M., & Boileau, C. (2009) · Human Mutation · doi:10.1002/humu.20882 · Cited by 255 · see citing works

Regulation of triglyceride metabolism by Angiopoietin-like proteins

Mattijssen, F., & Kersten, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.010 · Cited by 180 · see citing works

Identification of a New Functional Domain in Angiopoietin-like 3 (ANGPTL3) and Angiopoietin-like 4 (ANGPTL4) Involved in Binding and Inhibition of Lipoprotein Lipase (LPL)

Lee, E.-C., Desai, U., Gololobov, G., Hong, S., Feng, X., Yu, X., Gay, J. P., Wilganowski, N., Gao, C., Du, L.-L., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807899200 · Cited by 161 · see citing works

Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels

Mayer, G., Poirier, S., & Seidah, N. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805971200 · Cited by 154 · see citing works

Familial hypobetalipoproteinemia: genetics and metabolism

Schonfeld, G., Lin, X., & Yue, P. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-4473-0 · Cited by 154 · see citing works

Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis

Schonfeld, G., Patterson, B. W., Yablonskiy, D. A., Tanoli, T. S. K., Averna, M. R., Elias, N., Yue, P., & Ackerman, J. J. H. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m200342-jlr200 · Cited by 143 · see citing works

Characterization of Three Kindreds With Familial Combined Hypolipidemia Caused by Loss-of-Function Mutations of ANGPTL3

Pisciotta, L., Favari, E., Magnolo, L., Simonelli, S., Adorni, M. P., Sallo, R., Fancello, T., Zavaroni, I., Ardigò, D., Bernini, F., et al. (2011) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.111.960674 · Cited by 128 · see citing works

Quantitation of serum angiopoietin-like proteins 3 and 4 in a Finnish population sample

Robciuc, M. R., Tahvanainen, E., Jauhiainen, M., & Ehnholm, C. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m002618 · Cited by 107 · see citing works

A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice

Ando, Y., Shimizugawa, T., Takeshita, S., Ono, M., Shimamura, M., Koishi, R., & Furukawa, H. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300031-jlr200 · Cited by 101 · see citing works

Monogenic Hypocholesterolaemic Lipid Disorders and Apolipoprotein B Metabolism

Hooper, A. J., BOCKXMEER, F. M. V., & Burnett, J. R. (2005) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360500295113 · Cited by 99 · see citing works

Prevalence of ANGPTL3 and APOB Gene Mutations in Subjects With Combined Hypolipidemia

Noto, D., Cefalu, A. B., Valenti, V., Fayer, F., Pinotti, E., Ditta, M., Spina, R., Vigna, G. B., Yue, P., Kathiresan, S., et al. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.238766 · Cited by 82 · see citing works

Proprotein convertase subtilisin kexin 9: The third locus implicated in autosomal dominant hypercholesterolemia

Maxwell, K. N., & Breslow, J. L. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000162321.31925.a3 · Cited by 82 · see citing works

Genetics and regulation of angiopoietin-like proteins 3 and 4

Li, C. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000217896.67444.05 · Cited by 70 · see citing works

Identification of a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without APOB mutation

Martín-Campos, J. M., Roig, R., Mayoral, C., Martinez, S., Martí, G., Arroyo, J. A., Julve, J., & Blanco‐Vaca, F. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.11.020 · Cited by 65 · see citing works

Molecular Characterization of the NPC1L1 Variants Identified from Cholesterol Low Absorbers

Wang, L., 王, 丽., Wang, J., 王, 婧., Li, N., 李, 钠., Ge, L., 葛, 亮., Li, B.-L., 李, 伯., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.178368 · Cited by 63 · see citing works

Relationship between cholesterol synthesis and intestinal absorption is associated with cardiovascular risk

Weingärtner, O., Lütjohann, D., Böhm, M., & Laufs, U. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.01.003 · Cited by 61 · see citing works

Mutations in MTP gene in abeta- and hypobeta-lipoproteinemia

Leo, E. D., Lancellotti, S., Penachioni, J. Y., Cefalu, A. B., Averna, M. R., Pisciotta, L., Bertolini, S., Calandra, S., Gabelli, C., & Tarugi, P. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.12.004 · Cited by 58 · see citing works

Known mutations of apoB account for only a small minority of hypobetalipoproteinemia

Wu, J., Kim, J., Li, Q., Kwok, P., Cole, T. G., Cefalu, B., Averna, M. R., & Schonfeld, G. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32131-3 · Cited by 40 · see citing works

Apolipoprotein E genotyping in the Malay, Chinese and Indian ethnic groups in Malaysia—a study on the distribution of the different apoE alleles and genotypes

Seet, W. T., Tan, J. A. M. A., & Yen, T. S. (2004) · Clinica Chimica Acta · doi:10.1016/j.cccn.2003.11.001 · Cited by 39 · see citing works

A form of familial hypobetalipoproteinaemia not due to a mutation in the apolipoprotein B gene

Fazio, S., Sidoli, A., Vivenzio, A., Maietta, A., Giampaoli, S., Menotti, A., Antonini, R., Urbinati, G., Baralle, F. E., & RICCI, G. (1991) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1991.tb00304.x · Cited by 37 · see citing works

In Vivo Metabolism of ApoB, ApoA-I, and VLDL Triglycerides in a Form of Hypobetalipoproteinemia Not Linked to the ApoB Gene

Elias, N., Patterson, B. W., & Schonfeld, G. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.5.1309 · Cited by 36 · see citing works

Mean levels and distributions of some cardiovascular risk factors in Italy in the 1970's and the 1980's. The Italian RIFLE Pooling Project. Risk factors and life expectancy.

Menotti, A., Seccareccia, F., Lanti, M., Farchi, G., Conti, S., Dima, F., Scanga, M., Marenco, G., Falchero, M., & Idéo, G. (1995) · PubMed · Cited by 29 · see citing works

Common variants in the lipoprotein lipase gene, but not those in the insulin receptor substrate[ndash ]1, the [beta ]3-adrenergic receptor, and the intestinal fatty acid binding protein-2 genes, influence the lipid phenotypic expression in familial combined hyperlipidemia

Campagna, F., Montali, A., Baroni, M. G., Antonini, T., Ricci, G., Antonini, R., Verna, R., & Arca, M. (2002) · Metabolism · doi:10.1053/meta.2002.35197 · Cited by 21 · see citing works

Plasma non-cholesterol sterols in primary hypobetalipoproteinemia

Noto, D., Cefalu, A. B., Barraco, G., Fayer, F., Minà, M., Yue, P., Tarugi, P., Schonfeld, G., & Averna, M. R. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.10.050 · Cited by 9 · see citing works

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885 · see citing works

Physiological regulation of lipoprotein lipase

Kersten, S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.03.013 · Cited by 548 · see citing works

Inactivating Variants in <i>ANGPTL4</i> and Risk of Coronary Artery Disease

Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510926 · Cited by 497 · see citing works

ANGPTL3 deficiency and protection against coronary artery disease

Stitziel, N. O., Khera, A. V., Wang, X., Bierhals, A. J., Vourakis, A. C., Sperry, A. E., Natarajan, P., Klarin, D., Emdin, C. A., Zekavat, S. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.030 · Cited by 467 · see citing works

Hepatokines and metabolism: Deciphering communication from the liver

Jensen-Cody, S. O., & Potthoff, M. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101138 · Cited by 252 · see citing works

Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia

Ahmad, Z., Banerjee, P., Hamon, S., Chan, K., Bouzelmat, A., Sasiela, W. J., Pordy, R. C., Mellis, S. J., Dansky, H. M., Gipe, D. A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.039107 · Cited by 248 · see citing works

From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk

Shapiro, M. D., & Fazio, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306471 · Cited by 217 · see citing works

Angiopoietin-like 3 in lipoprotein metabolism

Kersten, S. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.119 · Cited by 220 · see citing works

ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys

Gusarova, V., Alexa, C. A., Wang, Y., Rafique, A., Kim, J. H., Buckler, D., Mintah, I. J., Shihanian, L. M., Cohen, J. C., Hobbs, H. H., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m054890 · Cited by 210 · see citing works

Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia

Rosenson, R. S., Gaudet, D., Hegele, R. A., Ballantyne, C. M., Nicholls, S. J., Lucas, K. J., San Martin, J., Zhou, R., Muhsin, M., Chang, T., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404147 · Cited by 213 · see citing works

Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance

Adam, R. C., Mintah, I. J., Alexa-Braun, C. A., Shihanian, L. M., Lee, J. S., Banerjee, P., Hamon, S. C., Kim, H. I., Cohen, J. C., Hobbs, H. H., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120000888 · Cited by 208 · see citing works

Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70

Bergmark, B. A., Marston, N. A., Bramson, C. R., Curto, M., Ramos, V., Jevne, A., Kuder, J. F., Park, J.-G., Murphy, S. A., Verma, S., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059266 · Cited by 216 · see citing works

Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement

Hegele, R. A., Borén, J., Ginsberg, H. N., Arca, M., Averna, M., Binder, C. J., Calabresi, L., Chapman, M. J., Cuchel, M., von Eckardstein, A., et al. (2020) · The Lancet Diabetes &amp; Endocrinology · doi:10.1016/s2213-8587(19)30264-5 · Cited by 204 · see citing works

Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion

Wang, Y., Gusarova, V., Banfi, S., Gromada, J., Cohen, J. C., & Hobbs, H. H. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m054882 · Cited by 189 · see citing works

Angptl3 Deficiency Is Associated With Increased Insulin Sensitivity, Lipoprotein Lipase Activity, and Decreased Serum Free Fatty Acids

Robciuc, M. R., Maranghi, M., Lahikainen, A., Rader, D. J., Bensadoun, A., Öörni, K., Metso, J., Minicocci, I., Ciociola, E., Ceci, F., et al. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.301397 · Cited by 176 · see citing works

Hypobetalipoproteinemia and abetalipoproteinemia

Welty, F. K. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000072 · Cited by 166 · see citing works

Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8

Sylvers-Davie, K. L., & Davies, B. S. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00195.2021 · Cited by 149 · see citing works

The role of ANGPTL3 in controlling lipoprotein metabolism

Tikka, A., & Jauhiainen, M. (2016) · Endocrine · doi:10.1007/s12020-015-0838-9 · Cited by 131 · see citing works

Novel and future lipid-modulating therapies for the prevention of cardiovascular disease

Brandts, J., & Ray, K. K. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00860-8 · Cited by 107 · see citing works

Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia

Wiegman, A., Greber‐Platzer, S., Ali, S., Reijman, M. D., Brinton, E. A., Charng, M., Srinivasan, S., Baker-Smith, C. M., Baum, S. J., Brothers, J. A., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.065529 · Cited by 98 · see citing works

Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis

Minicocci, I., Santini, S., Cantisani, V., Stitziel, N., Kathiresan, S., Arroyo, J. A., Martí, G., Pisciotta, L., Noto, D., Cefalù, A. B., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.p039875 · Cited by 97 · see citing works

An updated ANGPTL3-4-8 model as a mechanism of triglyceride partitioning between fat and oxidative tissues

Zhang, R., & Zhang, K. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101140 · Cited by 93 · see citing works

Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia

Ruscica, M., Zimetti, F., Adorni, M. P., Sirtori, C. R., Lupo, M. G., & Ferri, N. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104653 · Cited by 84 · see citing works

Chylomicrons: Advances in biology, pathology, laboratory testing, and therapeutics

Julve, J., Martín-Campos, J. M., Escolá‐Gil, J. C., & Blanco‐Vaca, F. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.02.004 · Cited by 85 · see citing works

Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial

Ray, K. K., Oru, E., Rosenson, R. S., Jones, J., Ma, X., Walgren, J., Haupt, A., Verma, S., Gaudet, D., Nicholls, S. J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00507-0 · Cited by 81 · see citing works

Broadening the Scope of Dyslipidemia Therapy by Targeting APOC3 (Apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3)

Ginsberg, H. N., & Goldberg, I. J. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.317966 · Cited by 83 · see citing works

Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia

Chen, P., Gao, W.-Y., Liou, J.-W., Lin, C.-Y., Wu, M., & Yen, J.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147310 · Cited by 80 · see citing works

Causal inference in health and disease: a review of the principles and applications of Mendelian randomization

Lovegrove, C. E., Howles, S., Furniss, D., & Holmes, M. V. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae136 · Cited by 80 · see citing works

Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease

Welty, F. K. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000663 · Cited by 71 · see citing works

Guidance for the diagnosis and treatment of hypolipidemia disorders

Bredefeld, C., Hussain, M. M., Averna, M. R., Black, D. D., Brin, M. F., Burnett, J. R., Charrière, S., Cuerq, C., Davidson, N. O., Deckelbaum, R. J., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.08.009 · Cited by 72 · see citing works

Angiopoietin-like proteins as therapeutic targets for cardiovascular disease: focus on lipid disorders

Morelli, M. B., Chavez, C., & Santulli, G. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1707806 · Cited by 64 · see citing works

Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects

Lupo, M. G., & Ferri, N. (2018) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd5030039 · Cited by 62 · see citing works

Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events

Raschi, E., Casula, M., Cicero, A. F. G., Corsini, A., Borghi, C., & Catapano, A. L. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108507 · Cited by 66 · see citing works

Updates in Drug Treatment of Severe Hypertriglyceridemia

Gouni-Berthold, I., Schwarz, J., & Berthold, H. K. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01140-z · Cited by 59 · see citing works

Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism

Minicocci, I., Tikka, A., Poggiogalle, E., Metso, J., Montali, A., Ceci, F., Labbadia, G., Fontana, M., Di Costanzo, A., Maranghi, M., et al. (2016) · Journal of Lipid Research · doi:10.1194/jlr.p066183 · Cited by 56 · see citing works

Update on Primary Hypobetalipoproteinemia

Hooper, A. J., & Burnett, J. R. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0423-3 · Cited by 58 · see citing works

Lipoprotein metabolism in familial hypercholesterolemia

Chemello, K., García‐Nafría, J., Gallo, A., Martı́n, C., Lambert, G. C., & Blom, D. J. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100062 · Cited by 54 · see citing works

Clinical and biochemical characteristics of individuals with low cholesterol syndromes: A comparison between familial hypobetalipoproteinemia and familial combined hypolipidemia

Costanzo, A. D., Leo, E. D., Noto, D., Cefalu, A. B., Minicocci, I., Polito, L., D’Erasmo, L., Cantisani, V., Spina, R., Tarugi, P., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.06.013 · Cited by 46 · see citing works

Angiopoietin-like protein 3 (ANGPTL3) deficiency and familial combined hypolipidemia

Tarugi, P., Bertolini, S., & Calandra, S. (2018) · Journal of Biomedical Research · doi:10.7555/jbr.32.20170114 · Cited by 44 · see citing works

Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis

Wiciński, M., Górski, K. M., Wódkiewicz, E., Walczak, M., Nowaczewska, M., & Malinowski, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072275 · Cited by 47 · see citing works

Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia

Fukami, H., Morinaga, J., Nakagami, H., Hayashi, H., Okadome, Y., Matsunaga, E., Kadomatsu, T., Horiguchi, H., Sato, M., Sugizaki, T., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100446 · Cited by 46 · see citing works

The Regulation of Triacylglycerol Metabolism and Lipoprotein Lipase Activity

Wen, Y., Chen, Y., & Konrad, R. J. (2022) · Advanced Biology · doi:10.1002/adbi.202200093 · Cited by 43 · see citing works

Metabolomic Signature of Angiopoietin-Like Protein 3 Deficiency in Fasting and Postprandial State

Tikkanen, E., Minicocci, I., Hällfors, J., Costanzo, A. D., D’Erasmo, L., Poggiogalle, E., Donini, L. M., Würtz, P., Jauhiainen, M., Olkkonen, V. M., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312021 · Cited by 41 · see citing works

The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease

Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40 · see citing works

Silencing of ANGPTL 3 (angiopoietin-like protein 3) in human hepatocytes results in decreased expression of gluconeogenic genes and reduced triacylglycerol-rich VLDL secretion upon insulin stimulation

Tikka, A., Soronen, J., Laurila, P., Metso, J., Ehnholm, C., & Jauhiainen, M. (2014) · Bioscience Reports · doi:10.1042/bsr20140115 · Cited by 39 · see citing works

Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins

Fazio, S., Minnier, J., Shapiro, M. D., Tsimikas, S., Tarugi, P., Averna, M. R., Arca, M., & Tavori, H. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-4043 · Cited by 38 · see citing works

Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long‐Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events

D’Erasmo, L., Minicocci, I., Costanzo, A. D., Pigna, G., Commodari, D., Ceci, F., Montali, A., Brancato, F., Stanca, I., Nicolucci, A., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.018932 · Cited by 39 · see citing works

The angiopoietin-like protein 3

Arca, M., Minicocci, I., & Maranghi, M. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283630cf0 · Cited by 37 · see citing works

Liraglutide protects cardiac function in diabetic rats through the PPARα pathway

Zhang, Q., Xiao, X., Zheng, J., Li, M., Yu, M., Ping, F., Wang, T., & Wang, X. (2018) · Bioscience Reports · doi:10.1042/bsr20180059 · Cited by 36 · see citing works

Angiopoietin-Like Proteins: Cardiovascular Biology and Therapeutic Targeting for the Prevention of Cardiovascular Diseases

Thorin, É., Labbé, P., Lambert, M., Mury, P., Dagher, O., Miquel, G., & Thorin‐Trescases, N. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.06.002 · Cited by 37 · see citing works

Hepatokines: unveiling the molecular and cellular mechanisms connecting hepatic tissue to insulin resistance and inflammation

Miao, X., Alidadipour, A., Saed, V., Sayyadi, F., Jadidi, Y., Davoudi, M., Amraee, F., Jadidi, N., & Afrisham, R. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02335-9 · Cited by 34 · see citing works

ANGPTL3 Deficiency and Risk of Hepatic Steatosis

D’Erasmo, L., Martino, M. D., Neufeld, T., Fraum, T. J., Kang, C. J., Burks, K. H., Costanzo, A. D., Minicocci, I., Bini, S., Maranghi, M., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.065866 · Cited by 33 · see citing works

Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia

Béliard, S., Saheb, S., Litzler-Renault, S., Vimont, A., Valéro, R., Bruckert, É., Farnier, M., & Gallo, A. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.320609 · Cited by 31 · see citing works

Advances in nucleic acid-targeted therapies for cardiovascular disease prevention

Makhmudova, U., Steinhagen‐Thiessen, E., Volpe, M., & Landmesser, U. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae136 · Cited by 30 · see citing works

New and emerging lipid-modifying drugs to lower LDL cholesterol

Kosmas, C. E., Pantou, D., Sourlas, A., Papakonstantinou, E. J., Uceta, R. E., & Guzman, E. (2021) · Drugs in Context · doi:10.7573/dic.2021-8-3 · Cited by 30 · see citing works

Angiopoietin-Like 3 Protein Inhibition: A New Frontier in Lipid-Lowering Treatment

Lang, W. R., & Frishman, W. H. (2019) · Cardiology in Review · doi:10.1097/crd.0000000000000258 · Cited by 27 · see citing works

Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial

Raal, F. J., Bergeron, J., Gaudet, D., Rosenson, R. S., SULLIVAN, D. R., Turner, T. A., Hegele, R. A., Ballantyne, C. M., Knowles, J. W., Leeper, N. J., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00290-6 · Cited by 25 · see citing works

GALNT2 regulates ANGPTL3 cleavage in cells and in vivo of mice

Li, X., Zhang, Y., Zhang, M., & Wang, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-73388-3 · Cited by 26 · see citing works

ANGPLT3: A novel modulator of lipid metabolism

Hassan, M. S. (2017) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2017.6 · Cited by 24 · see citing works

Structure-function analyses of microsomal triglyceride transfer protein missense mutations in abetalipoproteinemia and hypobetalipoproteinemia subjects

Walsh, M. T., Leo, E. D., Okur, İ., Tarugi, P., & Hussain, M. M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.07.015 · Cited by 24 · see citing works

Paeoniflorin regulates GALNT2-ANGPTL3-LPL pathway to attenuate dyslipidemia in mice

Xiao, H., Liang, L., Luo, Z.-F., & Sun, Z. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.08.006 · Cited by 24 · see citing works

A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease

Hu, X., Fan, J., Ma, Q., Han, L., Cao, Z., Xu, C., Luan, J., Jing, G., Nan, Y., Wu, T., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01456-z · Cited by 22 · see citing works

Structure and Function of Angiopoietin-like Protein 3 (ANGPTL3) in Atherosclerosis

Lu, X. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190621120523 · Cited by 22 · see citing works

Angiopoietin-like 3: An important protein in regulating lipoprotein levels

Burks, K. H., Basu, D., Goldberg, I. J., & Stitziel, N. O. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101688 · Cited by 21 · see citing works

Role of angiopoietin-like protein 3 in sugar-induced dyslipidemia in rhesus macaques: suppression by fish oil or RNAi

Butler, A. A., Graham, J. L., Stanhope, K. L., Wong, S. C., King, S. M., Bremer, A. A., Krauss, R. M., Hamilton, J., & Havel, P. J. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra119000423 · Cited by 20 · see citing works

New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia

Cesaro, A., Fimiani, F., Gragnano, F., Moscarella, E., Schiavo, A., Vergara, A., Akioyamen, L. E., D’Erasmo, L., Averna, M. R., Arca, M., et al. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.07.008 · Cited by 21 · see citing works

The influence of angiopoietin-like protein 3 on macrophages polarization and its effect on the podocyte EMT in diabetic nephropathy

Ma, Y., Chen, Y., Xu, H., & Du, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1228399 · Cited by 22 · see citing works

Contribution of mutations in low density lipoprotein receptor (LDLR) and lipoprotein lipase (LPL) genes to familial combined hyperlipidemia (FCHL): A reappraisal by using a resequencing approach

Minicocci, I., Prisco, C., Montali, A., Costanzo, A. D., Ceci, F., Pigna, G., & Arca, M. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.036 · Cited by 20 · see citing works

ANGPTL3 deficiency impairs lipoprotein production and produces adaptive changes in hepatic lipid metabolism

Burks, K. H., Xie, Y., Gildea, M. A., Jung, I., Mukherjee, S. K., Lee, P. C., Pudupakkam, U., Wagoner, R., Patel, V., Santana, K., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100500 · Cited by 19 · see citing works

Low cholesterol states: clinical implications and management

Gill, P. K., & Hegele, R. A. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2204932 · Cited by 19 · see citing works

ANGPTL3 Downregulation Increases Intracellular Lipids by Reducing Energy Utilization

Pennisi, G., Maurotti, S., Ciociola, E., Jamialahmadi, O., Bertolazzi, G., Mirarchi, A., Bergh, P., Scionti, F., Mancina, R. M., Spagnuolo, R., et al. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319789 · Cited by 18 · see citing works

Regulation of Energy Balance by the Hypothalamic Lipoprotein Lipase Regulator Angptl3

Kim, H.-K., Shin, M., Youn, B., Kang, G. M., Gil, S. Y., Lee, C. H., Choi, J. H., Lim, H. S., Yoo, H. J., & Kim, M.-S. (2014) · Diabetes · doi:10.2337/db14-0647 · Cited by 18 · see citing works

Analysis of circulating angiopoietin-like protein 3 and genetic variants in lipid metabolism and liver health: the DiOGenes study

Hess, A. L., Carayol, J., Blædel, T., Hager, J., Cara, A. D., Astrup, A. V., Saris, W. H. M., Larsen, L. H., & Valsesia, A. (2018) · Genes & Nutrition · doi:10.1186/s12263-018-0597-3 · Cited by 18 · see citing works

Angiopoietin-like protein 3, an emerging cardiometabolic therapy target with systemic and cell-autonomous functions

Ruhanen, H., Haridas, P. A. N., Jauhiainen, M., & Olkkonen, V. M. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158791 · Cited by 18 · see citing works

Functional and morphological vascular changes in subjects with familial combined hypolipidemia: An exploratory analysis

Minicocci, I., Cantisani, V., Poggiogalle, E., Favari, E., Zimetti, F., Montali, A., Labbadia, G., Pigna, G., Pannozzo, F., Zannella, A., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.05.053 · Cited by 18 · see citing works

Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry

D’Erasmo, L., Bini, S., Casula, M., Gazzotti, M., Bertolini, S., Calandra, S., Tarugi, P., Averna, M. R., Iannuzzo, G., Fortunato, G., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae036 · Cited by 17 · see citing works

Development of Antisense Drugs for Dyslipidemia

Yamamoto, T., Wada, F., & Harada‐Shiba, M. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv16001 · Cited by 17 · see citing works

Tissue expression and predicted protein structures of the bovine ANGPTL3 and association of novel SNPs with growth and meat quality traits

Chen, N., Ma, Y., Yang, T., Lin, F., Fu, W., Xu, Y., Li, F., Li, J. Y., & Gao, S. (2015) · animal · doi:10.1017/s1751731115000658 · Cited by 16 · see citing works

ANGPTL3 is part of the machinery causing dyslipidemia majorily via LPL inhibition in mastitis mice

Xiao, H., Wang, J., & Sun, Z. (2017) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2017.11.003 · Cited by 16 · see citing works

ANGPTL3 deficiency alters the lipid profile and metabolism of cultured hepatocytes and human lipoproteins

Ruhanen, H., Haridas, P. A. N., Minicocci, I., Taskinen, J., Palmas, F., Costanzo, A. D., D’Erasmo, L., Metso, J., Partanen, J., Dalli, J., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158679 · Cited by 16 · see citing works

Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation

Reeskamp, L. F., Tromp, T. R., Huijgen, R., Stroes, E. S. G., Hovingh, G. K., & Grefhorst, A. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.11.013 · Cited by 16 · see citing works

How ANGPTL3 Inhibition Will Help Our Clinical Practice?

Bini, S., Tramontano, D., Minicocci, I., Costanzo, A. D., Tambaro, F., D’Erasmo, L., & Arca, M. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01076-w · Cited by 15 · see citing works

Rare coding variants in CHRNB2 reduce the likelihood of smoking

Rajagopal, V. M., Watanabe, K., Mbatchou, J. S., Ayer, A. H., Quon, P., Sharma, D., Kessler, M. D., Praveen, K., Gelfman, S., Parikshak, N., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01417-8 · Cited by 15 · see citing works

Hepatokines, bile acids and ketone bodies are novel Hormones regulating energy homeostasis

Garruti, G., Baj, J., Cignarelli, A., Perrini, S., & Giorgino, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1154561 · Cited by 15 · see citing works

Evinacumab for treatment of familial hypercholesterolemia

Warden, B. A., & Duell, P. B. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.1955349 · Cited by 15 · see citing works

Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia

Pirillo, A., & Catapano, A. L. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2090242 · Cited by 14 · see citing works

Recent developments in the genetics of LDL deficiency

Hooper, A. J., & Burnett, J. R. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32835ca0d9 · Cited by 14 · see citing works

ANGPTL3 negatively regulates IL-1β-induced NF-κB activation by inhibiting the IL1R1-associated signaling complex assembly

Zhang, Y., Zhang, Z.-T., Wan, S.-Y., Yang, J. X., Wei, Y., Chen, H., Zhou, W.-Z., Song, Q., Niu, S., Zheng, L., et al. (2023) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjad053 · Cited by 13 · see citing works

Angiopoietin-like protein inhibitors: Promising agents for the treatment of familial hypercholesterolemia and atherogenic dyslipidemia

Vahdat‐Lasemi, F., Farhoudi, L., Hosseinikhah, S. M., Santos, R. D., & Sahebkar, A. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119235 · Cited by 14 · see citing works

Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia

Larouche, M., Khoury, É., Brisson, D., & Gaudet, D. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01179-y · Cited by 14 · see citing works

Clinical significance of angiopoietin-like protein 3 expression in patients with glioblastoma

WANG, P. F., Li, H. L., Qi, X., YAO, K., Han, S., Liu, N., Yang, Y., Li, S., & Yan, C. (2015) · Neoplasma · doi:10.4149/neo_2016_011 · Cited by 12 · see citing works

The Future of Lipid-Lowering Therapy

Zwol, W. H.-V., Rimbert, A., & Kuivenhoven, J. A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071085 · Cited by 12 · see citing works

Effects of Pemafibrate on LDL-C and Related Lipid Markers in Patients with MASLD: A Sub-Analysis of the PEMA-FL Study

Tanigawa, R., Nakajima, A., Eguchi, Y., Takahashi, H., Loomba, R. S., Suganami, H., Tanahashi, M., Saito, A., Iida, Y., & Yamashita, S. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65395 · Cited by 11 · see citing works

Syndromic Retinitis Pigmentosa: A Narrative Review

Janáky, M., & Braunitzer, G. (2025) · Vision · doi:10.3390/vision9010007 · Cited by 10 · see citing works

A Comprehensive Review of the Latest Approaches to Managing Hypercholesterolemia: A Comparative Analysis of Conventional and Novel Treatments: Part II

Jianu, N., Nițu, E.-T., Merlan, C., Nour, A., Buda, S., Suciu, M., Luca, S. A., Sbârcea, L., Andor, M., & Buda, V. O. (2025) · Pharmaceuticals · doi:10.3390/ph18081150 · Cited by 14 · see citing works

RNA Interference Targeting Liver Angiopoietin-Like Protein 3 Protects from Nephrotic Syndrome in a Rat Model Via Amelioration of Pathologic Hypertriglyceridemia

Zhao, Y., Goto, M., Vaziri, N. D., Khazaeli, M., Liu, H., Farahanchi, N., Khanifar, E., Farzaneh, T., Haslett, P. A. J., Moradi, H., et al. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000257 · Cited by 11 · see citing works

Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here

Hermel, M., Lieberman, M., Slipczuk, L. N., Rana, J. S., & Virani, S. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020459 · Cited by 11 · see citing works

ANGPTL3 (Angiopoietin‐Like 3) Preferentially Resides on High‐Density Lipoprotein in the Human Circulation, Affecting Its Activity

Kraaijenhof, J. M., Tromp, T. R., Nurmohamed, N. S., Reeskamp, L. F., Langenkamp, M., Levels, J. H. M., Boekholdt, S. M., Wareham, N. J., Hoekstra, M., Stroes, E. S. G., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030476 · Cited by 11 · see citing works

Apolipoprotein CIII and Angiopoietin-like Protein 8 are Elevated in Lipodystrophy and Decrease after Metreleptin

Lightbourne, M., Wolska, A. T., Abel, B. S., Rother, K. I., Walter, M. F., Kushchayeva, Y. S., Auh, S., Shamburek, R. D., Remaley, A. T., Muniyappa, R., et al. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa191 · Cited by 11 · see citing works

ANGPLT3 in cardio-metabolic disorders

Su, X. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06248-6 · Cited by 11 · see citing works

Prevalence of ANGPTL3 and APOB Gene Mutations in Subjects With Combined Hypolipidemia

Noto, D., Cefalu, A. B., Valenti, V., Fayer, F., Pinotti, E., Ditta, M., Spina, R., Vigna, G. B., Yue, P., Kathiresan, S., et al. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.238766 · Cited by 82 · see citing works

Familial combined hypolipidemia due to mutations in theANGPTL3gene

Calandra, S., Tarugi, P., Averna, M. R., & Bertolini, S. (2013) · Clinical Lipidology · doi:10.2217/clp.12.92 · Cited by 5 · see citing works

Characterization of Three Kindreds With Familial Combined Hypolipidemia Caused by Loss-of-Function Mutations of ANGPTL3

Pisciotta, L., Favari, E., Magnolo, L., Simonelli, S., Adorni, M. P., Sallo, R., Fancello, T., Zavaroni, I., Ardigò, D., Bernini, F., et al. (2011) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.111.960674 · Cited by 128 · see citing works

Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis

Minicocci, I., Santini, S., Cantisani, V., Stitziel, N., Kathiresan, S., Arroyo, J. A., Martí, G., Pisciotta, L., Noto, D., Cefalù, A. B., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.p039875 · Cited by 97 · see citing works

The first Japanese case with familial combined hypolipidemia without any complications caused by loss-of function variants in ANGPTL3: Case report

Tada, H., Kojima, N., Kawashiri, M., & Takamura, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29924 · Cited by 1 · see citing works